Is Eton Pharmaceuticals Stock a Good Investment?
Eton Pharmaceuticals Investment Advice | ETON |
- Examine Eton Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Eton Pharmaceuticals' leadership team and their track record. Good management can help Eton Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Eton Pharmaceuticals' business and its evolving consumer preferences.
- Compare Eton Pharmaceuticals' performance and market position to its competitors. Analyze how Eton Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Eton Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Eton Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eton Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eton Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Eton Pharmaceuticals Stock
Researching Eton Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 33.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.26. Eton Pharmaceuticals had not issued any dividends in recent years.
To determine if Eton Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eton Pharmaceuticals' research are outlined below:
| Eton Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 39.01 M. Net Loss for the year was (3.82 M) with profit before overhead, payroll, taxes, and interest of 14.32 M. | |
| Latest headline from finance.yahoo.com: Eton Pharmaceuticals Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags |
Eton Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eton Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eton Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Eton Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eton Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-16 | 2022-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2022-11-10 | 2022-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2020-08-12 | 2020-06-30 | -0.26 | -0.23 | 0.03 | 11 | ||
2019-11-14 | 2019-09-30 | -0.25 | -0.28 | -0.03 | 12 | ||
2024-05-09 | 2024-03-31 | -0.07 | -0.03 | 0.04 | 57 | ||
2023-05-11 | 2023-03-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2021-08-16 | 2021-06-30 | -0.14 | -0.1 | 0.04 | 28 | ||
2024-08-09 | 2024-06-30 | -0.07 | -0.12 | -0.05 | 71 |
Know Eton Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eton Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eton Pharmaceuticals backward and forwards among themselves. Eton Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eton Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-12-31 | 239 K | Wasatch Advisors Lp | 2024-12-31 | 231.3 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 214.9 K | Paradigm Capital Management, Inc. | 2024-12-31 | 200 K | Renaissance Technologies Corp | 2024-12-31 | 193.1 K | Susquehanna International Group, Llp | 2024-12-31 | 192.3 K | Acuitas Investments, Llc | 2024-12-31 | 185.8 K | Millennium Management Llc | 2024-12-31 | 138.9 K | Ubs Group Ag | 2024-12-31 | 135.4 K | Opaleye Management Inc | 2024-12-31 | 2.9 M | Ecor1 Capital, Llc | 2024-12-31 | 1.8 M |
Eton Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 236.92 M.Market Cap |
|
Eton Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.16) | (0.16) |
Determining Eton Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Eton Pharmaceuticals is a good buy. For example, gross profit margin measures Eton Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eton Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Eton Pharmaceuticals' management efficiency
Eton Pharmaceuticals has return on total asset (ROA) of (0.125) % which means that it has lost $0.125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.443) %, meaning that it created substantial loss on money invested by shareholders. Eton Pharmaceuticals' management efficiency ratios could be used to measure how well Eton Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.05. At this time, Eton Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Net Tangible Assets is likely to grow to about 12.2 M, while Non Currrent Assets Other are likely to drop about 10.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.94 | 1.22 | |
| Tangible Book Value Per Share | (0.40) | (0.38) | |
| Enterprise Value Over EBITDA | (127.11) | (133.46) | |
| Price Book Value Ratio | 14.12 | 14.83 | |
| Enterprise Value Multiple | (127.11) | (133.46) | |
| Price Fair Value | 14.12 | 14.83 | |
| Enterprise Value | 55 M | 71.5 M |
The management team at Eton Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.257 |
Basic technical analysis of Eton Stock
As of the 25th of March, Eton Pharmaceuticals shows the Downside Deviation of 4.43, mean deviation of 3.59, and Coefficient Of Variation of 1400.15. Eton Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Eton Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eton Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eton Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eton Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eton Pharmaceuticals' Outstanding Corporate Bonds
Eton Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eton Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eton bonds can be classified according to their maturity, which is the date when Eton Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Eton Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Eton Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0725 | |||
| Market Risk Adjusted Performance | 0.3542 | |||
| Mean Deviation | 3.59 | |||
| Semi Deviation | 4.26 | |||
| Downside Deviation | 4.43 | |||
| Coefficient Of Variation | 1400.15 | |||
| Standard Deviation | 4.67 | |||
| Variance | 21.82 | |||
| Information Ratio | 0.0771 | |||
| Jensen Alpha | 0.3579 | |||
| Total Risk Alpha | 0.5125 | |||
| Sortino Ratio | 0.0812 | |||
| Treynor Ratio | 0.3442 | |||
| Maximum Drawdown | 25.22 | |||
| Value At Risk | (6.17) | |||
| Potential Upside | 7.74 | |||
| Downside Variance | 19.66 | |||
| Semi Variance | 18.12 | |||
| Expected Short fall | (3.92) | |||
| Skewness | 0.0445 | |||
| Kurtosis | 0.5316 |
| Risk Adjusted Performance | 0.0725 | |||
| Market Risk Adjusted Performance | 0.3542 | |||
| Mean Deviation | 3.59 | |||
| Semi Deviation | 4.26 | |||
| Downside Deviation | 4.43 | |||
| Coefficient Of Variation | 1400.15 | |||
| Standard Deviation | 4.67 | |||
| Variance | 21.82 | |||
| Information Ratio | 0.0771 | |||
| Jensen Alpha | 0.3579 | |||
| Total Risk Alpha | 0.5125 | |||
| Sortino Ratio | 0.0812 | |||
| Treynor Ratio | 0.3442 | |||
| Maximum Drawdown | 25.22 | |||
| Value At Risk | (6.17) | |||
| Potential Upside | 7.74 | |||
| Downside Variance | 19.66 | |||
| Semi Variance | 18.12 | |||
| Expected Short fall | (3.92) | |||
| Skewness | 0.0445 | |||
| Kurtosis | 0.5316 |
Consider Eton Pharmaceuticals' intraday indicators
Eton Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eton Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Eton Pharmaceuticals Corporate Filings
10K | 18th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 14th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 7th of March 2025 An amendment to a previously filed Form 8-K | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Eton Stock media impact
Far too much social signal, news, headlines, and media speculation about Eton Pharmaceuticals that are available to investors today. That information is available publicly through Eton media outlets and privately through word of mouth or via Eton internal channels. However, regardless of the origin, that massive amount of Eton data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eton Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eton Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eton Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eton Pharmaceuticals alpha.
Eton Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Eton Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Eton Pharmaceuticals Historical Investor Sentiment
Investor biases related to Eton Pharmaceuticals' public news can be used to forecast risks associated with an investment in Eton. The trend in average sentiment can be used to explain how an investor holding Eton can time the market purely based on public headlines and social activities around Eton Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Eton Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eton Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Eton Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Eton Pharmaceuticals.
Eton Pharmaceuticals Corporate Management
| Danka Radosavljevic | Senior Operations | Profile | |
| James CPA | Treasurer CFO | Profile | |
| Kevin Guthrie | Executive Operations | Profile | |
| Scott Grossenbach | Senior Operations | Profile | |
| Ingrid Hoos | Senior Affairs | Profile | |
| Ipek ErdoganTrinkaus | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Eton Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.